Last Updated : April 19, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name Sort descending | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Victoza | Liraglutide | Diabetes Mellitus, Type 2 | Withdrawn | |||
| Victoza | Liraglutide | Diabetes mellitus, Type 2 | Do not list | Complete | ||
| Victrelis | Boceprevir | Hepatitis C, chronic | List with clinical criteria and/or conditions | Complete | ||
| Victrelis | Boceprevir | Hepatitis C, chronic | List with criteria/condition | Complete | ||
| Victrelis | Boceprevir | Hepatitis C, chronic | List with criteria/condition | Complete | ||
| Viibryd | vilazodone | CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer | Not filed | |||
| Vimizim | Elosulfase alfa | Mucopolysaccharidosis IVA (Morquio A syndrome) | Reimburse with clinical criteria and/or conditions | Complete | ||
| Vimizim | Elosulfase alfa | Mucopolysaccharidosis IVA (Morquio A syndrome) | Do not list | Complete | ||
| Vimpat | Lacosamide | Epilepsy, partial onset seizures | List with clinical criteria and/or conditions | Complete | ||
| Viread | Tenofovir disoproxil fumarate | HIV infection | Do not list | Complete |
Last Updated : April 19, 2024